Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Adenocarcinoma × Crizotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 5 Neuroblastoma 2 Neoplasms 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma 1 Lung Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Large Cell 1 Carcinoma 1 Adenocarcinoma 1

Interventions

zolbetuximab 2 Oxaliplatin 2 Afatinib 2 trastuzumab deruxtecan 1 tepotinib 1 repotrectinib 1 pralsetinib 1 brigatinib 1 Standard of Care 1 Pemetrexed 1 Leucovorin 1 Fluorouracil 1 Crizotinib 1 Cisplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02737501 2021-08-20

ALTA-1L

Takeda

Phase 3 Completed

275 enrolled 23 charts 2 FDA

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡